Goldman Sachs Maintains Buy on Calumet, Raises Price Target to $20
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $15 to $20.
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $15 to $20.